On August 8, Glaukos rose 5.46% in regular trading, trading at $180.26/share, with turnover of approximately $109 million. The rally follows the company's Q2 earnings release that substantially exceeded market expectations, combined with a wave of analyst price target upgrades.

Glaukos reported Q2 adjusted loss of $0.14 per share, narrowing significantly from $0.24 a year earlier and beating the consensus estimate of $0.22 loss by over 36%. Revenue reached $185.6 million, surpassing the $150.9 million estimate by approximately 23%, driven by continued strong adoption of its glaucoma product portfolio. The company also raised its full-year revenue guidance to $680 million-$700 million, well above the prior Street estimate of $630 million.

Following the results, multiple institutions raised their price targets: Needham lifted its target from $150 to $201, HC Wainwright raised to $195 from $168, and Truist had previously adjusted to $180 — all maintaining Buy ratings. The average analyst target now stands near $189.62, reflecting broad institutional confidence in the company's growth trajectory and path toward profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)